% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Herth:120384,
      author       = {I. Herth and S. Dietrich and A. Benner$^*$ and U. Hegenbart
                      and M. Rieger and P. Stadtherr and A. Bondong and T. H. Tran
                      and R. Weide and M. Hensel and W. Knauf and J. Franz-Werner
                      and M. Welslau and M. Procaccianti and M. Görner and J.
                      Meissner and T. Luft and S. Schönland and M. Witzens-Harig
                      and T. Zenz$^*$ and A. D. Ho and P. Dreger},
      title        = {{T}he impact of allogeneic stem cell transplantation on the
                      natural course of poor-risk chronic lymphocytic leukemia as
                      defined by the {EBMT} consensus criteria: a retrospective
                      donor versus no donor comparison.},
      journal      = {Annals of oncology},
      volume       = {25},
      number       = {1},
      issn         = {1569-8041},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-00817},
      pages        = {200 - 206},
      year         = {2014},
      abstract     = {In a single-center retrospective donor versus no-donor
                      comparison, we investigated if allogeneic stem cell
                      transplantation (alloSCT) can improve the dismal course of
                      poor-risk chronic lymphocytic leukemia (CLL).All patients
                      with CLL who were referred for evaluation of alloSCT within
                      a 7-year time frame and had a donor search indication
                      according to the EBMT criteria or because of Richter's
                      transformation were included. Patients for whom a matched
                      donor could be found within 3 months (matches) were compared
                      with patients without such a donor (controls). Primary end
                      point was overall survival measured from the 3-month
                      landmark after search initiation.Of 105 patients with donor
                      search, 97 (matches 83; controls 14) were assessable at the
                      3-month landmark. Matches and controls were comparable for
                      age, gender, time from diagnosis, number of previous
                      regimens, and remission status. Disregarding if alloSCT was
                      actually carried out or not, survival from the 3-month
                      landmark was significantly better in matches versus controls
                      [hazard ratio 0.38, $95\%$ confidence interval (CI)
                      0.17-0.85; P = 0.014]. The survival benefit of matches
                      remained significant on multivariate analysis.This study
                      provides first comparative evidence that alloSCT may have
                      the potential to improve the natural course of poor-risk CLL
                      as defined by the EBMT criteria.},
      cin          = {C060 / G100},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)G100-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24356631},
      doi          = {10.1093/annonc/mdt511},
      url          = {https://inrepo02.dkfz.de/record/120384},
}